FARMACIA HOSPITALARIA最新文献

{"title":"[Artículo traducido] Estabilidad de los medicamentos termolábiles a temperatura ambiente. Revisión","authors":"Paloma Suárez-Casillas ,&nbsp;Santiago José Lora-Escobar ,&nbsp;Elena Montecatine-Alonso ,&nbsp;Tao Li ,&nbsp;Hector Acosta-García","doi":"10.1016/j.farma.2025.04.001","DOIUrl":"10.1016/j.farma.2025.04.001","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study was to review and compile the available information, in an easily accessible format, regarding the stability of thermolabile drugs at room temperature (22–25 °C), according to information contained in summary of product characteristics (SmPC), published literature, and information provided by the manufacturing pharmaceutical companies.</div></div><div><h3>Methods</h3><div>Drugs included in our hospital that required storage at a temperature between 2 and 8 °C were selected. Medications used in clinical trials, frozen drugs, and compounded formulations were excluded. The first source of information consulted for stability data was the SmPC. In case of no information available, published literature and gray literature were reviewed. If information was not found through these sources, the manufacturing laboratory was contacted.</div><div>The results are shown in table format to make the information more manageable. The table contains the following information: Drug product, trade name, brand name (manufacturer), maximum stability at room temperature, and information source. Stability data from SmPC were included for all medications, and for those with additional information obtained through the sources used in the study, this was included in a separate column.</div></div><div><h3>Results</h3><div>A total of 203 thermolabile drugs were selected. Thirty seven (18.2%) had a stability of 24 h at room temperature, 36 (17.7%) had a stability of 48 h–1 week, 63 (31%) had a stability of 1 week–1 month, and 52 (25.6%) had a stability of more than 1 month. However, 12 drugs (6.3%) had a stability of less than 24 h, and 3 drugs (1.4%) had other stability data at room temperature.</div><div>Stability information for 95 (46.7%) drugs was obtained from the SmPC, 56 (27.5%) from published literature, and 36 (26.2%) from manufacturers. In 21 of these cases, the stability information was valid exclusively for a specific case, with particular storage conditions and for a specific batch of the product.</div></div><div><h3>Conclusion</h3><div>The number and impact of thermolabile drugs have increased exponentially in recent years. The vast majority of these drugs maintain adequate stability at room temperature for an acceptable period of time, with some remaining stable for relatively long periods. To date, our study presents the largest dataset on the stability of these drugs. Therefore, the results of our study constitute a highly useful and up-to-date tool for saving time and money in hospital pharmacy units. Pharmaceutical manufacturers should consider publishing stability study results under non-recommended storage conditions in the SmPC.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T328-T338"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Role of the pharmacy technician in the clinical trials unit of the pharmacy service of an oncohaematological hospital","authors":"Núria Farré Cabrerizo,&nbsp;Olalla Montero Pérez,&nbsp;Maria Emilia Miquel Zurita,&nbsp;Marina Badàs Moreno,&nbsp;Marta Company Martos,&nbsp;Gemma Garcia Deu,&nbsp;Jennifer Rodríguez Rojas,&nbsp;Mònica González Laguna,&nbsp;Sonia Narváez Seixa,&nbsp;Sandra Fontanals Martínez,&nbsp;Maria Perayre Badia","doi":"10.1016/j.farma.2025.06.008","DOIUrl":"10.1016/j.farma.2025.06.008","url":null,"abstract":"<div><div>In recent years, there has been a considerable increase in clinical trials in the field of oncohematology, an area in which new drugs are constantly emerging. In addition to the large number of available clinical trials, the growing complexity of the treatments for cancer is also a relevant factor. This situation has required a notable evolution and specialization of the functions and responsibilities of pharmacy technicians within the Clinical Trials Unit of the Pharmacy Service.</div><div>This article describes the role of the pharmacy technician in a Clinical Trials Unit of tan oncohematological hospital pharmacy service, with over 20 years of experience in clinical trials.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T321-T327"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Criteria for medication reconciliation in major orthopedic surgery in high-risk patients: A consensus based on the Delphi method","authors":"Mafalda Cavalheiro ,&nbsp;Jesús Cotrina Luque ,&nbsp;Gonçalo Duarte ,&nbsp;Patricia BSilva ,&nbsp;Cátia Pereira ,&nbsp;Miriam Capoulas ,&nbsp;Cláudia Santos","doi":"10.1016/j.farma.2024.10.016","DOIUrl":"10.1016/j.farma.2024.10.016","url":null,"abstract":"<div><h3>Background</h3><div>Medication reconciliation is relevant in transitional care, however, given limited resources, it is necessary to identify the patients who benefit most from this activity.</div></div><div><h3>Aim</h3><div>To validate criteria to identify patients at high risk of medication errors undergoing major orthopedic surgery.</div></div><div><h3>Method</h3><div>Delphi Method in 3 phases, April–June 2023, to obtain consensus on the inclusion criteria, previously defined. Each expert rated criteria according to a 5-point Likert scale. Consensus was assumed in round 1 if the rate average was ≥<!--> <!-->4 (inclusion) or &lt;<!--> <!-->2 (exclusion) and in rounds 2 and 3 if 50% of the responses were ≥<!--> <!-->4 (inclusion) or &lt;<!--> <!-->2 (exclusion). It was possible to suggest the inclusion of new criteria.</div></div><div><h3>Results</h3><div>10 experts from Faculties of Pharmacy and Medicine participated. In the first phase, consensus was reached on 18 criteria: polypharmacy, anticoagulants, oral chemotherapy (not hormone), immunosuppressants, antiretrovirals, antimyasthenics, insulin, corticoids, neuroleptics, antiarrhythmics, digoxin, carbamazepine, phenytoin, valproate, thyroid drugs, antiglaucoma, antiaggregants, and urgent surgery. Systemic antifungals and opioids were suggested. In the second phase, consensus was reached on 11 criteria: antiparkinsonics, beta-blockers, age ≥ 65 years, length of stay ≥<!--> <!-->5 days, lamotrigine, diuretics, antidepressants, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, anxiolytics, opioids, and systemic antifungals. In the last phase, 1 criterion reached consensus (sulfonylureas) and 1 criterion did not reach consensus (calcium channel blockers).</div></div><div><h3>Conclusions</h3><div>We develop and validate a list of 30 criteria to identify patients at high risk of experiencing medication errors undergoing major orthopedic surgery. These may help improve human resource management for clinical pharmacy activities by prioritizing patients who would benefit most.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 272-277"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Criterios para la conciliación terapéutica en la cirugía ortopédica mayor en pacientes de alto riesgo: un consenso basado en el método Delphi","authors":"Mafalda Cavalheiro ,&nbsp;Jesús Cotrina Luque ,&nbsp;Gonçalo Duarte ,&nbsp;Patricia B Silva ,&nbsp;Cátia Pereira ,&nbsp;Miriam Capoulas ,&nbsp;Cláudia Santos","doi":"10.1016/j.farma.2025.01.004","DOIUrl":"10.1016/j.farma.2025.01.004","url":null,"abstract":"<div><h3>Background</h3><div>Medication reconciliation is relevant in transitional care, however, given limited resources, it is necessary to identify the patients who benefit most from this activity.</div></div><div><h3>Aim</h3><div>To validate criteria to identify patients at high risk of medication errors undergoing major orthopedic surgery.</div></div><div><h3>Method</h3><div>Delphi Method in 3 phases, April to June 2023, to obtain consensus on the inclusion criteria, previously defined. Each expert rated criteria according to a 5-point Likert scale. Consensus was assumed in round 1 if the rate average was more than 4 (inclusion) or less than 2 (exclusion) and in round 2 and 3 if 50% of the responses were more than 4 (inclusion) or less than 2 (exclusion). It was possible to suggest the inclusion of new criteria.</div></div><div><h3>Results</h3><div>10 experts from Faculties of Pharmacy and Medicine participated. In the first phase, consensus was reached on 18 criteria: polypharmacy, anticoagulants, oral chemotherapy (not hormone), immunosuppressants, antiretrovirals, antimyasthenics, insulin, corticoids, neuroleptics, antiarrhythmics, digoxin, carbamazepine, phenytoin, valproate, thyroid drugs, anti-glaucoma, anti-aggregants, and urgent surgery. Systemic antifungals and opioids were suggested. In the second phase, consensus was reached on eleven criteria: anti-parkinsonics, beta-blockers, age more than<!--> <!-->65 years, length of stay more than 5 days, lamotrigine, diuretics, antidepressants, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, anxiolytics, opioids, and systemic antifungals. In the last phase, one criterion reached consensus (sulfonylureas) and one criterion did not reach consensus (calcium channel blockers).</div></div><div><h3>Conclusions</h3><div>We develop and validate a list of 30 criteria to identify patients at high risk of experiencing medication errors undergoing major orthopedic surgery. These may help improve human resource management for clinical pharmacy activities by prioritizing patients who would benefit most.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T272-T277"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Evaluation of trimethoprim-sulfamethoxazole prescribing and dosage optimisation in a tertiary care hospital","authors":"Maialen Inclán-Conde ,&nbsp;Clara Vila-Gallego ,&nbsp;Maite Vara-Urruchua ,&nbsp;Ana Victoria Aguirrezabal-Arredondo ,&nbsp;Óscar Luis Ferreiro-Benéitez ,&nbsp;Matxalen Vidal-García ,&nbsp;Pamela Ruiz-Rodríguez ,&nbsp;José Antonio Domínguez-Menéndez","doi":"10.1016/j.farma.2025.04.006","DOIUrl":"10.1016/j.farma.2025.04.006","url":null,"abstract":"<div><h3>Objective</h3><div>Evaluate the impact on improving the appropriateness of prescribing following a pharmaceutical intervention based on the review and optimisation of sulfamethoxazole-trimethoprim prescriptions.</div></div><div><h3>Methods</h3><div>A before-after intervention study was conducted in a tertiary hospital. The first period, or intervention period, was prospective and ran from September 2021 to January 2022. The second or post-intervention period was retrospective and covered the period March-December 2022.</div><div>In case of discrepancy between indication and prescribed and recommended dosage, the physician was notified and the degree of acceptance was recorded. In the post-intervention period, we retrospectively analysed the adequacy of the dosage, checking whether any intervention had been carried out by the Pharmacy Department. Statistical analysis was performed using the chi-square test.</div></div><div><h3>Results</h3><div>During the intervention period, 69 prescriptions were analysed, and 18 were found to be inappropriate (26%), 12 related to <em>Stenotrophomonas maltophilia</em> infection. In the post-intervention period, 129 prescriptions were reviewed, and 12 were considered inadequate (9%). Statistical analysis of the results obtained in both periods (18/69 and 12/129) showed statistically significant differences (<em>p</em> = 0.0082).</div></div><div><h3>Conclusions</h3><div>Pharmaceutical intervention in the review and optimisation of prescriptions improves the use of sulfamethoxazole-trimethoprim. The results obtained provide evidence of the importance of pharmaceutical review of such prescriptions.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T304-T307"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144133200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influencia de los polimorfismos del gen UGT1A1 en el tratamiento con sacituzumab govitecan. Revisión narrativa","authors":"Eva María Legido Perdices ,&nbsp;Fernando do Pazo Oubiña ,&nbsp;Elena Prado Mel ,&nbsp;Marta Miarons ,&nbsp;Betel Del Rosario García ,&nbsp;Fernando Gutiérrez Nicolás","doi":"10.1016/j.farma.2025.02.009","DOIUrl":"10.1016/j.farma.2025.02.009","url":null,"abstract":"<div><h3>Objective</h3><div>Sacituzumab govitecan is an antineoplastic therapy composed of a monoclonal antibody directed to the Trop2 antigen, conjugated to SN-38, an active metabolite of irinotecan that inhibits topoisomerase I. It is indicated for the treatment of metastatic triple-negative breast cancer in patients who have received at least two prior lines of treatment, with at least one in the metastatic context. SN-38 is eliminated by glucuronidation mediated by uridine diphosphate-glucuronosyltransferase-1A1 (UGT1A1) enzymes, present in the liver. Mutations in the <em>UGT1A1</em> gene decrease the expression of these enzymes, which increases the concentration of SN-38 and, consequently, increases the toxicity of the drug, especially in the form of neutropenia and diarrhea. This study aims to analyze the relationship between <em>UGT1A1</em> gene polymorphisms and toxicity associated with treatment with sacituzumab govitecan, in addition to reviewing the usefulness of genetic screening prior to starting therapy.</div></div><div><h3>Methods</h3><div>A non-systematic literature review was conducted on the impact of <em>UGT1A1</em> gene polymorphisms on the safety of sacituzumab govitecan treatment in patients with triple-negative breast cancer. The search included primary and secondary literature sources and communications from oncology conferences.</div></div><div><h3>Results</h3><div>Patients treated with sacituzumab govitecan with the <em>UGT1A1*28/*28</em> mutated genotype are more likely to experience grade more than 3 hematologic adverse events: neutropenia (approximate incidence of 60% compared to 40% for 1/*1 and 1/*28 genotypes), febrile neutropenia (18% homozygotes vs. 5% heterozygotes and 3% wild-type), grade more than 3 anemia (15% vs. 6% and 4%, respectively); as well as grade more than 3 diarrhea (24% vs. 13% and 6%, respectively). Additionally, treatment discontinuation rates are higher in *28/*28 individuals (6% compared to 1% heterozygotes and 2% wild-type).</div></div><div><h3>Conclusions</h3><div>Patients homozygous for the <em>UGT1A1*28</em> allele are at significantly increased risk of developing serious adverse events. Despite the clear relationship between <em>UGT1A1</em> polymorphisms and sacituzumab-govitecan toxicity, the review suggests that there is insufficient consensus on the need for systematic genetic screening. However, the findings indicate that such screening could be useful for identifying patients at risk and personalizing sacituzumab govitecan therapy.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 339-345"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022 SEFH national survey on hospital pharmacy services in Spain: Human resources, infrastructure, technology, information systems, education and research","authors":"Montserrat Pérez-Encinas ,&nbsp;Eva Negro-Vega ,&nbsp;Cecilia M. Fernández-Llamazares","doi":"10.1016/j.farma.2025.05.006","DOIUrl":"10.1016/j.farma.2025.05.006","url":null,"abstract":"<div><h3>Purpose</h3><div>To present results of the 2022 SEFH-Survey on Spanish Hospital Pharmacy Departments covering care, staffing, resources, technology, education, and research.</div></div><div><h3>Methods</h3><div>A cross-sectional descriptive study via a voluntary online survey sent to 353 hospitals in Spain. Data were collected from July–December 2022. Long-stay hospitals and correctional facilities were excluded.</div></div><div><h3>Results</h3><div>Response rate was 54.1%. Public hospitals represented 62.6%. Only 10.1% of departments operated 24/7, rising to 39.3% in larger hospitals. Half lacked continuous care service. Outpatients' services operated in mornings and afternoons in 54.8% of them (78.6% in larger centers). Telepharmacy for outpatients reached 57.7% of hospitals. ISO 9000 standards were followed by 70.7% and 14.4% adopted the Joint Commission model.</div><div>Each department had on average 7.0 specialist pharmacists (8.8 in public; 3.9 in private), increasing to 13.4 in larger hospitals. Of these, 3.8 pharmacists worked at least half-time in clinical units. Pharmacy technicians were the most common non-pharmacist professionals (mean: 6.9). Including residents, 9.936 professionals worked in Hospital Pharmacy Departments nationwide.</div><div>Automated dispensing carousels averaged 0.4 (horizontal) and 1.1 (vertical) per department. Automated dispensing systems covered 19.8% of beds. Robotic outpatient dispensing existed in 20.0% of hospitals. Technology for sterile workflow was used in 45.3%, 10.0% had robotics for cytostatic compounding and 61.7% smart infusion pumps.</div><div>Pharmaceutical care was provided in emergency services in 39.8% of hospitals, rising to 67.4 in larger ones. In home hospitalization, it was offered at 32.5% of departments, rising to 60.7% in centers with over 1000 beds.</div><div>Sterile formulations were prepared in 82.3% of departments; 15.7% managed advanced therapies. Drug level monitoring was measured in 16.1%, and 43.1% issued pharmacokinetics reports. Pharmacogenetic reports were produced in 8.7%.</div><div>On average pharmacy departments attended 3.635 outpatients, totaling 1,28 million nationwide. Cytostatic preparations averaged 31,199 and 46,263 in hospitals with over 500 and 1000 beds, respectively. Clinical trials per department averaged 424.</div><div>A total of 321 pharmacists were associate university professors, 401 held board certifications, and there were 2.3 PhD holders per department.</div></div><div><h3>Conclusion</h3><div>Hospital Pharmacy Departments are advancing in clinical integration, pharmacokinetics, automation, traceability, and outpatient care, though staffing remains limited and disparities persist. Teaching is strong, yet research remains modest.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 312-320"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocolo para la adaptación y consenso del cuestionario Community Pharmacy Survey on Patient Safety Culture a la Farmacia Hospitalaria en España","authors":"Juan Manuel Rodríguez-Camacho ,&nbsp;José Manuel Caro-Teller ,&nbsp;Sergio Plata-Paniagua ,&nbsp;Juan Alfredo Montero-Delgado ,&nbsp;Inés Jiménez-Lozano ,&nbsp;Carmen María Cuadros-Martínez","doi":"10.1016/j.farma.2024.10.002","DOIUrl":"10.1016/j.farma.2024.10.002","url":null,"abstract":"<div><h3>Introduction</h3><div>The Community Pharmacy Survey on Patient Safety Culture (CPSOPSC) is a tool created by the Agency for Healthcare Research and Quality and used in the United States to assess the patient safety culture among community pharmacy workers. This survey has been adapted for use in hospital pharmacies in other countries. However, it has not yet been implemented in Spanish hospital pharmacies due to the lack of an applicable version in Spain. This project aims to adapt and reach a consensus on the CPSOPSC for its subsequent use as a tool to improve patient safety in hospital pharmacies in Spain.</div></div><div><h3>Methods</h3><div>This non-clinical study will be developed in different phases: obtaining the necessary permissions, reviewing the literature to identify studies on the use of the CPSOPSC in hospital pharmacies, adapting the survey's questions to the sociocultural context, reaching a consensus on the questions using the Delphi-Rand/UCLA methodology with a panel of patient safety experts. These experts, who are hospital pharmacists, will evaluate the adapted survey in several rounds, using a Likert scale and telematic workshops to adjust the questions. Finally, a software application will be developed for the implementation, completion, and data management of the survey.</div></div><div><h3>Discussion</h3><div>Adapting the CPSOPSC to hospital pharmacies in Spain may be a useful tool for measuring the patient safety culture in this context. Through the Delphi-Rand/UCLA methodology, expert consensus and the relevance of the survey are ensured. Additionally, the creation of a computer application will facilitate data collection and analysis, promoting its use among professionals. The resulting survey from this project can identify specific needs and areas for improvement in Spanish hospital pharmacies, being useful for future actions aimed at improving patient safety.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 308-311"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] A decade of experience with biosimilar monoclonal antibodies","authors":"Isabel Río Álvarez,&nbsp;Encarnación Cruz-Martos","doi":"10.1016/j.farma.2025.07.006","DOIUrl":"10.1016/j.farma.2025.07.006","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T269-T271"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Messenger RNA as a new strategy against cancer","authors":"Eduardo Tejedor Tejada ,&nbsp;Begoña Gómez Pérez ,&nbsp;Garbiñe Lizeaga Cundin","doi":"10.1016/j.farma.2025.03.017","DOIUrl":"10.1016/j.farma.2025.03.017","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Page T350"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}